Table 1.
Incidence of interstitial lung disease exacerbation in prospective trials of first-line platinum doublet chemotherapy in non–small cell lung cancer patients with interstitial lung disease.
| Study | Number of patients (Study design) |
Chemotherapy regimen | ILD exacerbation (%) |
|---|---|---|---|
| Kenmotsu et al31 | 94 (phase II) |
Carboplatin + Nab-paclitaxel | 4.3 |
| Asahina et al32 | 36 (phase II) |
Carboplatin + Nab-paclitaxel | 5.6 |
| Minegishi et al33 | 18 (Pilot) |
Carboplatin + Weekly Paclitaxel | 5.6 |
| Fukuizumi et al34 | 35 (phase II) |
Carboplatin + Weekly Paclitaxel | 12.1 |
| Sekine et al35 | 21 (phase II) |
Carboplatin + S-1 | 9.5 |
| Hanibuchi et al36 | 33 (phase II) |
Carboplatin + S-1 | 6.1 |
Abbreviation: ILD, interstitial lung disease.